We show that inhibition of IAPs could increase the sensitivity to bortezomib, thus suggesting that a combination of IAP antagonists with bortezomib would be beneficial for MM patients harboring TRAF3 mutations leading to hyperactivation of the NF-κB pathway and more dependency on the canonical pathway. This evidence concerns the gene NFKB1 and Miyoshi myopathy.